lundi 18 avril 2016

Onco Actu du 18 avril 2016

5.12 Immunothérapies

Despite The Glitz, Sean Parker's Cancer Institute Could Be Something Special [Forbes]

Gene editing technology could help engineer better cancer targeting immune cells [Cancer Research UK]

5.6.4 ESMO - Poumon

ELCC 2016 News: Osimertinib Combined With Durvalumab in EGFR-mutant Non-Small-Cell Lung Cancer [ESMO]

ELCC 2016 News: Updates from CheckMate 063 and 017 Trials Confirm Nivolumab Efficacy in Patients with Advanced Platinum-Refractory Squamous NSCLC [ESMO]

ELCC 2016 News: Novel Durvalumab plus Gefitinitib Shows Promise in EGFR Mutated NSCLC [ESMO]

ELCC 2016 News: Comprehensive Molecular Profiling Shows Disparity Between Primary NSCLC Tumours and Metastases [ESMO]

5.9.3 AACR - mélanome

First Presentation of Two-Year Overall Survival Data for Opdivo® (nivolumab) in Combination with Yervoy® (ipilimumab) Showed Superior Efficacy Versus Yervoy Alone in Advanced Melanoma [BMS]

SPF30 Sunscreens Delay Melanoma Incidence in Preclinical Model [AACR]

Five-year Survival Rates For Nivolumab-treated Metastatic Melanoma Patients Much Higher Than Historical Rates [AACR]

Bristol's Opdivo Shows Benefits in Cancer Immunotherapy Trial [Wall Street Journal]

5.9.5 AACR - T-cell immunothérapies

Kite Cancer Therapy Responses in Solid Tumors Sustained in Trial [Bloomberg]

CD4 T-cell Immunotherapy Targeting MAGE-A3 is Safe, and Shows Early Clinical Responses in Patients with Metastatic Cancer [AACR]

AACR – Mage-A3 double-whammy hits Kite [EP Vantage]

5.9.7 AACR - divers

New Investigational Targeted Therapeutic, Entrectinib, Shows Early Promise Against a Range of Cancer Types

Seattle Genetics Highlights Novel Antibody-Drug Conjugate (ADC) Technology Advances at the American Association for Cancer Research (AACR) Annual Meeting [Seattle Genetics]

Targeted Therapy Shows Continued Promise in Patients Whose Tumors Had NTRK Gene Fusions [AACR]

New RAF-targeted Therapeutic Shows Early Promise Against Tumors With BRAF and RAS Mutations [AACR]

Low-fat diet linked to better breast cancer survival, but doubts remain [STAT]

Loxo Cancer Drug Targets Gene Mutation With Durable Responses in Early Study [TheStreet]

6. Lutte contre les cancers

European Data Protection Authorities Chime in on Privacy Shield [CDT]

Get Involved [National Cancer Institute]

6.10 Politiques

Why A Woman With Cancer Supports Hillary Clinton For President [Forbes]

6.11 Patients

Cambridge professor reduced to tears by noisy hospital before death [The Telegraph]

6.4 Médico-éco

Report Identifies Considerations for Alternative Payment Models for Cancer Care [AACR]

6.6 Publications

Three HER2-cancer review papers tagged with expressions of concern [Retraction Watch]